Outbound Relationships |
Type |
Target |
Active |
Characteristic |
Refinability |
Group |
Values |
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
Is a |
Product containing caffeine (medicinal product) |
false |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
Is a |
Oral caffeine (product) |
false |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
Caffeine |
false |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
Bronchodilator |
false |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
Stimulant (substance) |
false |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
Xanthine |
false |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
Is a |
Product containing paracetamol (medicinal product) |
false |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
Is a |
Product containing dihydrocodeine (medicinal product) |
false |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
Paracetamol |
false |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
Dihydrocodeine bitartrate |
false |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
Non-opioid analgesics |
false |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
Dihydrocodeine |
false |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
Is a |
Product containing caffeine and dihydrocodeine tartrate and paracetamol |
false |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
Opioid receptor agonist |
false |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
Phosphodiesterase inhibitor |
false |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
Has manufactured dose form |
A solid single-dose form that is a shell made of gelatin or other substances. The contents of the shell may be a solid, semi-solid or liquid. |
false |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
Xanthine |
false |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
tartrate de dihydrocodéine |
false |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
Is a |
Oral caffeine (product) |
false |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
Has manufactured dose form |
Oral capsule |
true |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
Is a |
Product containing paracetamol in oral dose form (medicinal product form) |
false |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
Has basis of strength substance (attribute) |
tartrate de dihydrocodéine |
false |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
Has presentation strength numerator value |
16 |
false |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
Has presentation strength numerator unit (attribute) |
mg |
true |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
Has presentation strength denominator value |
un |
false |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
Has presentation strength denominator unit (attribute) |
Capsule (unit of presentation) |
true |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
Has presentation strength numerator unit (attribute) |
mg |
true |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
Has presentation strength denominator value |
un |
false |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
Has presentation strength denominator unit (attribute) |
Capsule (unit of presentation) |
true |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
Has presentation strength numerator unit (attribute) |
mg |
true |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
3 |
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
Has presentation strength denominator value |
un |
false |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
3 |
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
Has presentation strength denominator unit (attribute) |
Capsule (unit of presentation) |
true |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
3 |
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
Has basis of strength substance (attribute) |
Paracetamol |
true |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
3 |
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
Has presentation strength numerator value |
356.4 |
false |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
3 |
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
Paracetamol |
false |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
Has basis of strength substance (attribute) |
Paracetamol |
false |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
Has presentation strength numerator value |
356.4 |
false |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
Caffeine |
false |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
Has basis of strength substance (attribute) |
Caffeine |
false |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
Has presentation strength numerator value |
30 |
false |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
tartrate de dihydrocodéine |
false |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
3 |
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
Has basis of strength substance (attribute) |
tartrate de dihydrocodéine |
false |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
3 |
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
Has presentation strength numerator value |
16 |
false |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
3 |
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
Has precise active ingredient |
Caffeine |
false |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
Has unit of presentation |
Capsule (unit of presentation) |
true |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
Has precise active ingredient |
tartrate de dihydrocodéine |
false |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
Has precise active ingredient |
Paracetamol |
true |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
3 |
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
Is a |
Product containing caffeine and dihydrocodeine and paracetamol in oral dose form (medicinal product form) |
false |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
Count of base of active ingredient |
trois |
false |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
Is a |
Caffeine and dihydrocodeine and paracetamol only product in oral dose form |
true |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
Has basis of strength substance (attribute) |
tartrate de dihydrocodéine |
true |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
Has precise active ingredient |
tartrate de dihydrocodéine |
true |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
Has precise active ingredient |
Caffeine |
true |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
Has basis of strength substance (attribute) |
Caffeine |
true |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
|